Cargando…

A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study

INTRODUCTION: The efficacy of prolonged-release fampridine (PR-FAM) may extend in multiple sclerosis (MS) beyond walking ability. The objective of this study was to evaluate the effect of PR-FAM treatment on cognition, fatigue, depression, and quality of life (QoL) in adult patients with MS in a rea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitsikostas, Dimos D., Doskas, Triantafyllos, Gkatzonis, Stylianos, Fakas, Nikolaos, Maltezou, Maria, Papadopoulos, Dimitrios, Gourgioti, Rania, Mitsias, Panayiotis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932964/ https://www.ncbi.nlm.nih.gov/pubmed/33528792 http://dx.doi.org/10.1007/s12325-020-01606-5

Ejemplares similares

Fampridine and quality of life in individuals with multiple sclerosis
por: Sagawa, Yoshimasa, et al.
Publicado: (2016)

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
por: Albrecht, Philipp, et al.
Publicado: (2018)

Social Cognition Impairments in Association to Clinical, Cognitive, Mood, and Fatigue Features in Multiple Sclerosis: A Study Protocol
por: Doskas, Triantafyllos K., et al.
Publicado: (2023)

Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis—An Explorative Study
por: Mamoei, Sepehr, et al.
Publicado: (2021)

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial
por: Hupperts, Raymond, et al.
Publicado: (2016)

Managing HAM/TSP with Fampridine
por: Menna-Barreto, M Marcio
Publicado: (2014)

Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine
por: Sola-Valls, Núria, et al.
Publicado: (2018)

Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report
por: Müller, Mona Klara Ros, et al.
Publicado: (2022)

Aging, Cellular Senescence, and Progressive Multiple Sclerosis
por: Papadopoulos, Dimitrios, et al.
Publicado: (2020)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine
por: Kouremenos, Evangelos, et al.
Publicado: (2019)

Central motor conduction time may predict response to fampridine in patients with multiple sclerosis
por: Zeller, D, et al.
Publicado: (2014)

Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function
por: Rabadi, Meheroz H., et al.
Publicado: (2013)

Lack of Attention to the Administration of Fampridine as a Symptomatic Drug in Iranian Multiple Sclerosis Patients
por: Moghadasi, Abdorreza Naser
Publicado: (2021)

Observational Study Assessing Demographic, Economic and Clinical Factors Associated with Access and Utilization of Health Care Services of Patients with Multiple Sclerosis under Treatment with Interferon Beta-1b (EXTAVIA)
por: Hadjigeorgiou, Georgios, et al.
Publicado: (2014)

Correction: Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA)
por: Hadjigeorgiou, Georgios, et al.
Publicado: (2015)

Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)
por: Keune, Philipp M., et al.
Publicado: (2015)

Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment
por: Ahdab, Rechdi, et al.
Publicado: (2019)

Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
por: Castelnovo, Giovanni, et al.
Publicado: (2021)

Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE
por: Hupperts, Raymond, et al.
Publicado: (2022)

Prolonged-Release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: A Pilot, Double-Blind, Randomized, Placebo-Controlled Study
por: Jacques, François, et al.
Publicado: (2018)

The Dimensionality of the Multidimensional Fatigue Inventory (MFI-20) Derived From Healthy Adults and Patient Subpopulations: A Challenge for Clinicians
por: Bakalidou, Daphne, et al.
Publicado: (2022)

Patient and treatment characteristics and safety outcomes of patients with relapsing-remitting multiple sclerosis treated with natalizumab in Greece: Results from the multicenter, 5-year prospective observational study ‘TOPICS greece’
por: Karanasios, Panagiotis, et al.
Publicado: (2021)

Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double‐blind, placebo‐controlled cross‐over trial
por: Kanhai, Kawita M. S., et al.
Publicado: (2019)

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
por: Hobart, Jeremy, et al.
Publicado: (2018)

Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases
por: Prugger, Michael, et al.
Publicado: (2013)

Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study ‘TOPICS Greece’
por: Efthimios, Dardiotis, et al.
Publicado: (2021)

Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece
por: Dardiotis, Efthymios, et al.
Publicado: (2022)

Monoclonal Antibodies as Neurological Therapeutics
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Cluster headache: a quasi-rare disorder needing a reappraisal
por: Martelletti, Paolo, et al.
Publicado: (2015)

Treating Spontaneous Intracranial Hypotension with an Anesthetic Modality: The Role of the Epidural Blood Patch †
por: Masourou, Zoi, et al.
Publicado: (2022)

Impairment in selenocysteine synthesis as a candidate mechanism of inducible coagulopathy in COVID-19 patients
por: Vavougios, George D., et al.
Publicado: (2021)

Treating primary headaches – management of migraine
por: Mitsikostas, Dimos D
Publicado: (2013)

Refractory Headache: One Term does Not cover All – A Statement of the European Headache Federation
por: Lampl, Christian, et al.
Publicado: (2014)

PD38 - Clinical features and natural history of cold contact urticaria in children
por: Pananaki, Anna, et al.
Publicado: (2014)

Gleaning after the European Headache Federation consensus statement on refractory chronic migraine
por: Martelletti, Paolo, et al.
Publicado: (2014)

Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study
por: Deftereos, Spyros N., et al.
Publicado: (2018)

B-Cell Targeted Therapies in Patients with Multiple Sclerosis and Incidence of Headache: A Systematic Review and Meta-Analysis
por: Mavridis, Theodoros, et al.
Publicado: (2022)

High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma: Application to in vivo perfusion study
por: Achanti, Suneetha, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gq84e7g69ukhk6umfutdjc0i5a